Ventyx Biosciences, Inc. (NASDAQ:VTYX) Insider William J. Sandborn Sells 3,494 Shares

Posted by Defense World Staff on Aug 9th, 2023

Ventyx Biosciences, Inc. (NASDAQ:VTYX – Get Free Report) insider William J. Sandborn sold 3,494 shares of the firm’s stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $32.86, for a total value of $114,812.84. Following the transaction, the insider now directly owns 24,194 shares of the company’s stock, valued at approximately $795,014.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Ventyx Biosciences Price Performance

Ventyx Biosciences stock opened at $33.06 on Wednesday. The stock has a fifty day simple moving average of $34.90 and a two-hundred day simple moving average of $36.89. Ventyx Biosciences, Inc. has a 12 month low of $16.24 and a 12 month high of $47.25.

Ventyx Biosciences (NASDAQ:VTYX – Get Free Report) last issued its quarterly earnings data on Thursday, May 11th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.04). Analysts expect that Ventyx Biosciences, Inc. will post -2.8 earnings per share for the current fiscal year.

Institutional Trading of Ventyx Biosciences

Several large investors have recently modified their holdings of VTYX. Bank of New York Mellon Corp grew its holdings in shares of Ventyx Biosciences by 38.1% in the first quarter. Bank of New York Mellon Corp now owns 24,242 shares of the company’s stock worth $329,000 after acquiring an additional 6,688 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Ventyx Biosciences by 3.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 73,803 shares of the company’s stock worth $1,002,000 after acquiring an additional 2,482 shares during the period. State Street Corp grew its holdings in shares of Ventyx Biosciences by 65.2% in the first quarter. State Street Corp now owns 171,195 shares of the company’s stock worth $2,323,000 after acquiring an additional 67,590 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Ventyx Biosciences by 57.8% in the second quarter. JPMorgan Chase & Co. now owns 11,984 shares of the company’s stock worth $147,000 after acquiring an additional 4,391 shares during the period. Finally, Rhumbline Advisers bought a new stake in shares of Ventyx Biosciences in the second quarter worth $311,000.

Analyst Ratings Changes

A number of research analysts recently weighed in on VTYX shares. Credit Suisse Group started coverage on Ventyx Biosciences in a research report on Wednesday, June 14th. They set an “outperform” rating and a $63.00 price objective for the company. 500.com reaffirmed a “reiterates” rating on shares of Ventyx Biosciences in a research report on Friday, May 12th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $57.67.

Read Our Latest Report on VTYX

About Ventyx Biosciences

(Get Free Report)

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.